Ads
related to: astrazeneca oncology r&d careers work from homeus.jobrapido.com has been visited by 1M+ users in the past month
jobs2careers.com has been visited by 100K+ users in the past month
Large Employment Site (>10 Million Unique Visitors Per Month) - TAtech
Search results
Results from the WOW.Com Content Network
The AstraZeneca R&D facility in Mölndal near Gothenburg, Sweden The new AstraZeneca Corporate HQ under construction in Cambridge, United Kingdom AstraZeneca develops, manufactures and sells pharmaceutical and biotechnology products to treat disorders in the oncology , cardiovascular , gastrointestinal , infection , neuroscience , respiratory ...
The consolidation of AstraZeneca's global R&D footprint will have an impact on sites in the United States. About 1,200 positions will leave Wilmington, while there will be an increase of about 300 ...
Baselga was born on 3 July 1959, in Barcelona in Spain. [5] He received his M.D. and Ph.D. degrees from the Autonomous University of Barcelona in 1982. [6] He completed a fellowship in Medical Oncology at Memorial Sloan-Kettering Cancer Center in New York, and subsequently stayed on as a faculty member of its Breast Medicine Service.
In December 2016, Pfizer acquired AstraZeneca's small-molecule antibiotics business for $1.575 billion. [ 97 ] [ 98 ] [ 99 ] In January 2018, Pfizer announced that it would end its work on research into treatments for Alzheimer's disease and Parkinsonism (a symptom of Parkinson's disease and other conditions).
A total of 1,600 jobs were to be relocated over three years, mainly to Cambridge, but the company planned to continue non-R&D work at the site. [8] In March 2014, Alderley Park was purchased by Manchester Science Parks – a partnership between Manchester's academic centres and local councils, and investment company Bruntwood .
[3] [4] AstraZeneca subsequently acquired MedImmune LLC, [5] which it combined with CAT to form a global biologics R&D division called MedImmune. [6] CAT was often described as the 'jewel in the crown' of the British biotechnology industry [ 7 ] and during the latter years of its existence was the subject of frequent acquisition speculation.